Aethlon Medical Announces HIV-AIDS Research Collaboration

San Diego, CA - Aethlon Medical, Inc., a pioneer in developing medical devices to treat infectious disease, announced it has initiated a research collaboration to study the in vitro effectiveness of the Aethlon Hemopurifier to clear the Human Immunodeficiency Virus (HIV) from blood. The studies are being conducted through a collaboration established with ImQuest Biosciences, an infectious disease research organization based in Frederick, Maryland. The studies will document the rate at which the Aethlon Hemopurifier captures infectious forms of HIV, including multi-drug resistant strains of the virus. The studies will also identify the capture rate of gp120, a toxin shed from the surface of HIV, which causes apoptosis (programmed cell death) of immune cells. Depletion of immune cells is the hallmark of AIDS. The goal of the studies will be to reinforce and expand upon HIV data previously obtained by Aethlon researchers. In HIV care, the Hemopurifier is targeted to fill treatment voids of concern to all HIV-infected individuals.

• As an adjunct therapy able to extend and enhance the benefit of antiviral drug regimens by inhibiting the proliferation of drug resistant HIV and immunosuppressive toxins.
• As a non-drug therapy to maintain viral load suppression during structured treatment interruptions (STI), also known as "drug holidays".

SOURCE: Aethlon Medical